TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Physician reported outcomes after first chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in WOMAC A Pain Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate-vigorous physical activity minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Efficacy for physical activity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of the 9 Hole Peg Test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sleep quality assessed by validated sleep questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in sleep quality assessed by electronic equipment
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in fecal short chain fatty acid (SCFA) concentration as assessed by micromoles per gram (μmol/g)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fecal microbiome composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence of febrile seizure
Endpoint domain: Adverse events/effects
Primary endpoint: Validation of the mobile DSST application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Peak Aerobic Capacity (VO2-peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of Vorinostat Bortezomib Maintenance Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Daily Pain Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: time of tolerance acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of subjects abstinent from all opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective clearance of HSV-1 genome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of reblindness in participants
Endpoint domain: Adverse events/effects
Primary endpoint: HSV-1 virus testing outcome of the intervention eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area under the curve (AUC) of change in body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Microbiological Response to MK0826 Compared to Meropenem
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical Response to MK0826 Compared to Meropenem
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum Walking Speed Reached
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Walking Time Reached
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Changes From Study Baseline in Cholesterol, Glucose, HDL-C, LDL-C, and Triglycerides at Discharge Day (Day 19)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Study Baseline Over Time in Endothelial Function: Reactive Hyperemia Index (RHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rupture of galenic prevalence of at least one molecule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain threshold measured by Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) movement score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical results of bisphosphonate vs. denosmab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone health outcomes
Primary endpoint: Post Concussive Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Montgomery Asberg Depression Rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post Cesarean section febrile morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent Probability of Progression-free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Percent Probability of Event-free Survival (EFS)
Endpoint domain: Mortality/survival
Primary endpoint: changes in renal function and structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of women who successfully complete abortion without surgical intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False negative rate of positron emission tomography (PET)/computed tomography (CT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False negative rate of sentinel lymph node mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants reaching the composite endpoint
Endpoint domain: Mortality/survival
Primary endpoint: changes in keratotic nodular size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Brachial - ankle pulse wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brachial - ankle index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: No major stroke or death within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: No major territorial stroke or neurological death within 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Cytokine levels associated with pulmonary fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fibroblast activity in pulmonary fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bias of FloTrac Arterial Pressure Cardiac Output (L/Min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Precision of FloTrac Arterial Pressure Cardiac Output (L/Min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bias of ClearSight Arterial Pressure Cardiac Output (L/Min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Precision of ClearSight Arterial Pressure Cardiac Output (L/Min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time spent by ED physician on patient contact
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: VT of [18F]PBR111
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of betatrophin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in melatonin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Confirmed complete response or partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expulsion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of incomplete abortions warranting surgical evacuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: discharge delay
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes of quality of life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Response similarity to OEQ items
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cancer control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Temperature profile at various tissue depths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Received the Herpes Zoster Vaccine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: FEV1 variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intention to take nPEP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of participants evaluated for HCV infection
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Iron excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative hard cardiac events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resolution of Sub-retinal Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Proportion of optimal surgical field score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum observed serum concentration (Cmax) of TCZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration-time curve from time zero to last quantifiable concentration (AUClast) of TCZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mobility of hypogastric artery during cardiac cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Characterize displacement during cardiac cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intracranial progression-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Concentration of Plasma Serum vitamin D level (25OHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Description of Functional capacity efficiency
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intensity of non specific muscle pain (myalgia)
Endpoint domain: Adverse events/effects
Primary endpoint: Description of the improvement in Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subjective stroke risk perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subjective bleeding risk perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in number of new brain lesions detected on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acceptable safety profile
Endpoint domain: Adverse events/effects
Primary endpoint: Mean total hospital cost per subject
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Self Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient understanding of fistula anatomy and surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Difference in Fecal Calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pathologic complete and partial response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Retained
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incident COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in GERDq Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of mosaicing algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement rate of IGA-LCL Wrinkle Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in inflammatory and non-inflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs and Symptoms of Local Irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma and urine concentrations of belinostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of falls prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of sadness prediction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity and specificity of eating less well prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity and specificity of swollen leg prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Levator ani avulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Genital hiatus ballooning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endogenous LH secretion pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of the intestinal and urinary microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients with pituitary tumor enlargement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cuff leak volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of explicit recall of events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Patients With Fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Functional Hepatic Nitrogen Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Freedom from Major Adverse Limb Event (MALE)
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from Perioperative Death (POD)
Endpoint domain: Mortality/survival
Primary endpoint: Predictors for severe disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of changes of anterior corneal surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasonographic myocardial performance index values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma levels of study drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of functional pituitary adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: remission and recurrence rate of pituitary surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in NIH stroke scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hepatic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of time in the therapeutic anticoagulation range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Volumetric extent of resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cell Yield and Viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OSDI Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: apnea rate (number of apneas of ≥5 seconds/hour)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subjective Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Engagement in Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: migration of tibial component
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Psychiatric Hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: CRTd responders rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in upper extremity strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: partial pressure CO2 (pCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hidradenitis Suppurativa European Research Group (HISERG) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer specific traumatic stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dietary habits
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Sexual functioning
Endpoint domain: Life impact
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Efficacy of esomeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tolerability of esomeprazole
Endpoint domain: Adverse events/effects
Primary endpoint: Forced Expiratory Volume at One Second (FEV1) Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced Vital Capacity (FVC) Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak Expiratory Flow Rate (PEFR) Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of patients who fail to receive adjuvant therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of patients who fail to complete adjuvant therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Survival at one, three and six months
Endpoint domain: Mortality/survival
Primary endpoint: gene signal strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of Abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: admission rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: frailty scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percent of Eosinophils in Sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximal Percentage Decrease in Forced Expiratory Volume in 1 Second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diagnostic yield in esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of serum creatinine elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of end-stage renal disease or death
Endpoint domain: Mortality/survival
Primary endpoint: Tympanometry-Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safest and maximum tolerated dose regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline of PANSS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of use of advance directives
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Urinary concentration of methotrexate and its major metabolite 7-OH-methotrexate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Daptomycin plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of retinal non-perfusion areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of sector visual field progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: learning words and phrases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delphi response rate differences
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mesh erosion
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Complete Metabolic Response (CMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Clinic Systolic Blood Pressure (SBP) at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Far Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Contrast Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Near Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hazard Rate
Endpoint domain: Mortality/survival
Primary endpoint: Objective tumour response (CR and PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Corrected QT Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Impairment of finger motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Triggering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days to achieve complete enteral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety of administering cetuximab
Endpoint domain: Adverse events/effects